Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

CMG   negative

Noted as experiencing weakness in consumer discretionary spending, particularly in the 25-to-35 demographic.

---

APGE   positive

Company announced positive interim Phase 1b clinical trial results showing favorable safety profile and robust FeNO suppression in asthma patients. Multiple clinical readouts are anticipated in 2026, the company has strong cash position of $913 million with runway into H2 2028, and there is potential for Phase 3 initiation and 2029 launch of lead candidate. The expansion of zumilokibart beyond dermatology into respiratory indications demonstrates pipeline diversification and validates the 'pipeline-in-a-product' strategy.

---

#zumilokibart #APG777 #Phase 1b trial #asthma #atopic dermatitis #FeNO suppression #anti-IL-13 antibody #clinical trial results #Phase 3 #2026 milestones

APGE